Effects of sodium-glucose cotransporter 2 inhibitors on serum uric acid in patients with type 2 diabetes mellitus: A systematic review and network meta-analysis.

Xiaodong Hu Yue YangXiaona HuXiaomeng JiaHongzhou LiuMinjie WeiZhaohui Lyu

Published in: Diabetes, obesity & metabolism (2021)

SGLT-2 inhibitors could significantly reduce SUA levels in patients with T2DM, particularly luseogliflozin (1 and 10 mg) and dapagliflozin (5 mg) possess the best effects. Therefore, SGLT-2 inhibitors look extremely promising as an antidiabetes treatment option in patients with T2DM with high SUA.

Keyphrases

uric acid
metabolic syndrome
type diabetes
glycemic control
replacement therapy